Pruritus
VIDEO: Livmarli reduces serum bile acids and pruritus in PFIC, Alagille syndrome
In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.
FDA approves Bylvay for cholestatic pruritus due to Alagille syndrome
The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.
FDA expands Livmarli label to include infants with pruritus aged 3 months or older
The FDA has approved labeling changes for Livmarli, reducing the age of prescribing to infants with Alagille syndrome from 1 year to 3 months for the treatment of cholestatic pruritus, according to a Mirum Pharmaceuticals press release.
Linerixibat may relieve itch in primary biliary cholangitis-associated pruritus
Linerixibat induced a dose-dependent reduction in itch among patients with primary biliary cholangitis-associated pruritus, according to results published in Clinical Gastroenterology and Hepatology.
VIDEO: Livmarli reduces pruritus in progressive familial intrahepatic cholestasis subtypes
WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.
VIDEO: Bylvay improves pruritus, reduces serum bile acids in Alagille syndrome
WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.
Sometimes opioids, gabapentinoids may be best treatment for itching
LAS VEGAS — Antihistamines are not always the answer for pruritis in pain and advanced illness, Laura Meyer-Junco, PharmD, BCPS, CPE, said during a presentation at PAINWeek 2022.
Scratching provides high pleasure for patients with chronic spontaneous urticaria
Patients with chronic spontaneous urticaria experience more pleasure from scratching itches compared with patients with other skin conditions, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Difelikefalin well-tolerated for 64 weeks among patients with CKD-pruritus on hemodialysis
Use of difelikefalin was generally well-tolerated for up to 64 weeks among patients with chronic kidney disease-associated pruritus treated by hemodialysis, according to data published in Kidney Medicine.
Pruritus, atopic dermatitis gene expression downregulated by difelikefalin treatment
BOSTON — Pruritus and atopic dermatitis-related gene expression were altered after treatment with difelikefalin, according to a study presented at the American Academy of Dermatology Annual Meeting.